Management of chordoma and chondrosarcoma with definitive dose-escalated single-fraction spine stereotactic radiosurgery
CONCLUSION: Definitive dose-escalated SSRS to 24 Gy in 1 fraction appears to be a safe and effective treatment for achieving durable local control in chordoma or chondrosarcoma involving the spine, and may hold particular importance as a low-morbidity alternative to surgery in selected cases.PMID:37667065 | DOI:10.1007/s11060-023-04432-1 (Source: Cancer Control)
Source: Cancer Control - September 4, 2023 Category: Cancer & Oncology Authors: Alexander D Sherry Sean Maroongroge Brian De Behrang Amini Anthony P Conley Andrew J Bishop Chenyang Wang Thomas Beckham Martin Tom Tina Briere Jing Li Debra N Yeboa Mary Frances McAleer Robert North Claudio E Tatsui Laurence D Rhines Amol J Ghia Source Type: research
Management of chordoma and chondrosarcoma with definitive dose-escalated single-fraction spine stereotactic radiosurgery
ConclusionDefinitive dose-escalated SSRS to 24 Gy in 1 fraction appears to be a safe and effective treatment for achieving durable local control in chordoma or chondrosarcoma involving the spine, and may hold particular importance as a low-morbidity alternative to surgery in selected cases. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - September 4, 2023 Category: Cancer & Oncology Source Type: research
MiR-4270 acts as a tumor suppressor by directly targeting Bcl-xL in human osteosarcoma cells
Chondrosarcomas and osteosarcomas are malignant bone tumors with a poor prognosis when unresectable or metastasized. Moreover, radiotherapy and chemotherapy could be ineffective. MiRNAs represent an alternative therapeutic approach. Based on high-throughput functional screening, we identified four miRNAs with a potential antiproliferative effect on SW1353 chondrosarcoma cells. Individual functional validations were then performed in SW1353 cells, as well as in three osteosarcoma cell lines. The antiproliferative and cytotoxic effects of miRNAs were evaluated in comparison with a positive control, miR-342-5p. The cytotoxic ...
Source: Frontiers in Oncology - August 31, 2023 Category: Cancer & Oncology Source Type: research
A rare presentation of Maffucci syndrome: A case report and literature review
Exp Ther Med. 2023 Jul 25;26(3):435. doi: 10.3892/etm.2023.12134. eCollection 2023 Sep.ABSTRACTMaffucci syndrome is an extremely rare disease which can manifest symptoms as early as childhood. It is estimated that there have been <300 cases reported globally; however, this number is likely to be an underestimate. Maffucci syndrome is characterized by multiple enchondromas and soft tissue hemangiomas, which can cause growth and developmental malformations. In addition to bone deformities, pathological fractures and a loss of mobility, patients with Maffucci syndrome may develop secondary central chondrosarcoma and have a...
Source: Experimental and Therapeutic Medicine - August 21, 2023 Category: General Medicine Authors: Yue-Peng Wang Wen-Jia Di Shi-Lei Qin Su Yang Zhen Wang Yun-Feng Xu Peng-Fei Han Source Type: research
Dedifferentiated Chondrosarcoma: Diagnostic Controversies and Emerging Therapeutic Targets
AbstractPurpose of ReviewThe pathogenesis of dedifferentiated chondrosarcoma is controversial, and no genetic abnormality has consistently been identified in the disease. Focusing on the diagnostic challenges encountered in dedifferentiated chondrosarcoma, the following review aims at summarizing the tumor ’s active neoplastic pathways while highlighting therapeutic modalities that could potentially be explored to enhance patient survivorship.Recent FindingsOwing to the challenging examination of small needle biopsy sampling as well as the disease ’s overlapping morphological and immunohistochemical features with other...
Source: Current Oncology Reports - August 21, 2023 Category: Cancer & Oncology Source Type: research
Surgical management and final outcomes of chondrosarcoma of the temporomandibular joint: case series and comprehensive literature review
Surgical management for chondrosarcoma of the temporomandibular joint (TMJ) is challenging due to the anatomical location involving the facial nerve and the functional joint. The purpose of this case series wa... (Source: World Journal of Surgical Oncology)
Source: World Journal of Surgical Oncology - August 19, 2023 Category: Cancer & Oncology Authors: Hyun Jun Oh, Hye-Jung Yoon, Kyung-Hoe Huh, Bongju Kim, Ik-Jae Kwon, Soung Min Kim, Joo Yong Park, Sung Weon Choi and Jong-Ho Lee Tags: Research Source Type: research
Combined and staged retrosigmoid, extended middle fossa, and endoscopic transnasal approach to a petroclival chondrosarcoma: how I do it
ConclusionA combined approach to selected petroclival tumors can maximize safe resection. (Source: Acta Neurochirurgica)
Source: Acta Neurochirurgica - August 12, 2023 Category: Neurosurgery Source Type: research
Natural history of intraosseous low-grade chondroid lesions of the proximal humerus
DiscussionLow-grade cartilaginous lesions of the proximal humerus without concerning imaging findings can be managed with conservative treatment and the risk of malignant transformation is very low. Patients with a clear source of their shoulder pain unrelated to their tumor and without concerning characteristics on imaging can be managed with serial annual radiographic imaging. Patients undergoing surgery for these indolent tumors are likely to experience persistent pain even after surgery. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - August 11, 2023 Category: Cancer & Oncology Source Type: research
Radiotherapy in bone sarcoma: the quest for better treatment option
Bone sarcomas are rare tumors representing 0.2% of all cancers. While osteosarcoma and Ewing sarcoma mainly affect children and young adults, chondrosarcoma and chordoma have a preferential incidence in people... (Source: BMC Cancer)
Source: BMC Cancer - August 11, 2023 Category: Cancer & Oncology Authors: Marie-Ana ïs Locquet, Mehdi Brahmi, Jean-Yves Blay and Aurélie Dutour Tags: Review Source Type: research
Anti-tumor effects of deubiquitinating enzyme inhibitor PR-619 in human chondrosarcoma through reduced cell proliferation and endoplasmic reticulum stress-related apoptosis
This study aimed to investigate the impact of PR-619 on chondrosarcoma both in vitro and in vivo. Two human chondrosarcoma cell lines, SW11353 and JJ012, were utilized. Cell viability was assessed using an MTT assay, while flow cytometry enabled the detection of apoptosis and cell cycle progression. Western blotting analyses were conducted to evaluate apoptosis, cell stress, and endoplasmic reticulum (ER) stress. Furthermore, the in vivo anti-tumor effects of PR-619 were examined using a xenograft mouse model. The results revealed that PR-619 induced cytotoxicity, apoptosis, and cell cycle arrest at the G0/G1 stage by acti...
Source: Cell Research - August 10, 2023 Category: Cytology Authors: Wei-Chou Lin Yen-Lin Chiu Kuan-Lin Kuo Po-Ming Chow Chen-Hsun Hsu Shih-Ming Liao Jun-Ren Dong Shih-Chen Chang Shing-Hwa Liu Tsai-Jung Liu Fu-Shun Hsu Kuo-Chuan Wang Yi-Chih Lin Chen-Chih Chang Kuo-Yuan Huang Source Type: research
Radiotherapy in bone sarcoma: the quest for better treatment option
BMC Cancer. 2023 Aug 11;23(1):742. doi: 10.1186/s12885-023-11232-3.ABSTRACTBone sarcomas are rare tumors representing 0.2% of all cancers. While osteosarcoma and Ewing sarcoma mainly affect children and young adults, chondrosarcoma and chordoma have a preferential incidence in people over the age of 40. Despite this range in populations affected, all bone sarcoma patients require complex transdisciplinary management and share some similarities. The cornerstone of all bone sarcoma treatment is monobloc resection of the tumor with adequate margins in healthy surrounding tissues. Adjuvant chemo- and/or radiotherapy are often ...
Source: Cancer Control - August 10, 2023 Category: Cancer & Oncology Authors: Marie-Ana ïs Locquet Mehdi Brahmi Jean-Yves Blay Aur élie Dutour Source Type: research
Cancers, Vol. 15, Pages 3924: Dedifferentiated Chondrosarcoma from Molecular Pathology to Current Treatment and Clinical Trials
na M. Czarnecka
Dedifferentiated chondrosarcoma (DDCS) is a rare subtype of chondrosarcoma, a primary cartilaginous malignant neoplasm. It accounts for up to 1&ndash;2% of all chondrosarcomas and is generally associated with one of the poorest prognoses among all chondrosarcomas with the highest risk of metastasis. The 5-year survival rates range from 7% to 24%. DDCS may develop at any age, but the average presentation age is over 50. The most common locations are the femur, pelvis humerus, scapula, rib, and tibia. The standard treatment for localised disease is surgical resection. Most patients are diagnosed i...
Source: Cancers - August 1, 2023 Category: Cancer & Oncology Authors: Weronika Zaj ąc Julia Dr óżdż Weronika Kisielewska Weronika Karwowska Monika Dudzisz- Śledź Agnieszka E. Zaj ąc Aneta Borkowska Anna Szumera-Cie ćkiewicz Bart łomiej Szostakowski Piotr Rutkowski Anna M. Czarnecka Tags: Review Source Type: research
